825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Material Contracts
Vaxcyte Q2 2025 Financial Results and VAX-31 Vaccine Update
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Business Update
Changes in Board, Management or Compensation
Annual Report to Security Holders
Investor Presentation
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Q2
FY 2023
Q3
Q1
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership